Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current ...

Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA’s upside hinges on Intismeran’s ability to scale across multiple tumor types ...

Moderna (NASDAQ:MRNA) stock is in focus as cancer-vaccine optimism and a pending Nasdaq-100 addition anchor the mRNA developer's healthcare headlines today.

Moderna’s dramatic ascent this year has been fueled by optimism that its personalized cancer vaccine could reshape oncology and redefine the company beyond its pandemic-era success. That promise may ...

Investors Should Know: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma ...

With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term.